ENGNW · enGene Therapeutics Inc.
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Codification ("ASC") 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities as of April 30, 2026 will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months.”View the 10-Q filed Jun 15, 2026
Price & Indicators
The closing range uses available history since Jul 23, 2026; less than a full year is stored.
Up next
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders illustrative — not investment adviceIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and marketable securities | $266.3M | As of July 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENGNW
this stock
enGene Therapeutics Inc.
|
$103.88M | — | — | — | — |
|
VRTX
Vertex Pharmaceuticals Inc
|
$134.22B | +16.8% | +46.2% | 30.8 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.02B | +5.4% | +20.8% | 20.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.03B | +626.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 78.9%
- Reported
- 6 of 70
- Top holder
- FCPM III SERVICES B.V.
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENGNW | +6.7% | -21.2% | — | -46.7% | — |
| SPY | -0.1% | +1.3% | +5.6% | +1.3% | +13.3% |
| vs SPY | +6.8% | -22.4% | — | -48.0% | — |